Clinical Trial Update: A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function [Phase 1]

View source ↗

Summary

Phase 1 study evaluating pharmacokinetics and safety of oral mobocertinib in participants with moderate to severe hepatic impairment and normal hepatic function…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Impairment

Drugs mentioned

• mobocertinib (mobocertinib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Hepatic Impairment, Healthy Volunteers | Phase 1 | Status: COMPLETED | Results posted: 2023-11-03